Back to top
more

HOOKIPA Pharma (HOOK)

(Delayed Data from NSDQ)

$0.88 USD

0.88
146,780

+0.05 (6.08%)

Updated Aug 8, 2025 03:47 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 36.11% and 21.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ChromaDex (CDXC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of -12.50% and 8.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Allogene Therapeutics (ALLO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 14.75% and 7.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -29.41% and 30.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Paratek (PRTK) delivered earnings and revenue surprises of 5.71% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -233.33% and 93.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CorMedix (CRMD) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of 21.74% and 84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fstar Therapeutics, Inc. (FSTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fstar Therapeutics, Inc. (FSTX) delivered earnings and revenue surprises of 9.52% and 10.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25% and 2.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dynavax Technologies (DVAX) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -8.33% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Alnylam (ALNY) delivered earnings and revenue surprises of -3.63% and 12.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -22.64% and 9.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate HOOKIPA Pharma Inc. (HOOK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 6.25% and 5.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -12.96% and -26.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: HOOKIPA Pharma Inc. (HOOK) Q3 Earnings Expected to Decline

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers

by Zacks Equity Research

HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.

Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 0.00% and -1.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate HOOKIPA Pharma Inc. (HOOK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) Soars 7.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 0.00% and 38.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is a Surprise Coming for HOOKIPA (HOOK) This Earnings Season?

by Zacks Equity Research

HOOKIPA (HOOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 17.86% and 0.98%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate HOOKIPA Pharma Inc. (HOOK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.